HER2 BINDING PROTEINS BASED ON DI-UBIQUITIN MUTEINS

The present invention relates to new Her2 binding molecules based on di-ubiquitin muteins. The invention further refers to Her2 binding proteins optionally fused or conjugated to a moiety modulating pharmacokinetics or to a therapeutically or diagnostically active component. The invention further re...

Full description

Saved in:
Bibliographic Details
Main Authors BOSSE-DOENECKE, EVA, FIEDLER, ERIK, HAUPTS, ULRICH, ZWARG, MADLEN, SETTELE, FLORIAN, GLOSER, MANJA
Format Patent
LanguageEnglish
French
Published 26.01.2017
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to new Her2 binding molecules based on di-ubiquitin muteins. The invention further refers to Her2 binding proteins optionally fused or conjugated to a moiety modulating pharmacokinetics or to a therapeutically or diagnostically active component. The invention further relates to the use of these Her2 binding proteins in medicine, preferably for use in the diagnosis or treatment of cancer. La présente invention concerne de nouvelles molécules de liaison à Her2 à base de di-ubiquitine mutéines. L'invention concerne en outre des protéines de liaison à Her2 optionnellement fusionnées ou conjuguées à une fraction de modulation de la pharmacocinétique ou à un composant actif sur le plan thérapeutique ou diagnostique. L'invention concerne en outre l'utilisation de ces protéines de liaison à Her2 en médecine, de préférence pour une utilisation dans le diagnostic ou le traitement du cancer.
Bibliography:Application Number: CA20162991814